Revenue
2022
2023
2024
2025
Fusion Antibodies plc (FAB)
Price£0.1175Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £2.0M | £1.1M | £2.9M | £4.8M |
| Operating expenses | £2.2M | £2.2M | £3.4M | £3.8M |
| Operating income | −£1.8M | −£2.3M | −£2.9M | −£1.3M |
| Operating margin | −90.53% | −201.32% | −98.52% | −27.61% |
| EBITDA | −£1.7M | −£2.1M | −£2.5M | −£573,000 |
| EBITDA margin | −84.94% | −181.69% | −85.59% | −11.94% |
| Net income | −£1.7M | −£2.2M | −£2.6M | −£1.2M |
| Net profit margin | −87.18% | −195.95% | −89.49% | −25.01% |
| Basic EPSper basic share | -£0.02 | -£0.04 | -£0.10 | -£0.05 |
| Diluted EPSper diluted share | -£0.02 | -£0.04 | -£0.10 | -£0.05 |
Owners
Reported major voting-rights holders
2.76%of voting rights
Maven Capital Partners UK LLPNotified Nov 21, 2025
View holders
| Holder | Voting rights |
|---|---|
| 2.76%Nov 21, 2025 · 3.14M votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: FCA voting-rights notice ↗Updated Oct 21, 2026